A-186253, a specific antagonist of the α4β2 nAChRs: Its properties and potential to study brain nicotinic acetylcholine receptors

Neuropharmacology

Volumn 47, Issue 4, 2004, Pages 538-557

  Itier, Valérie ^a   Schönbächler, Roland ^b,c   Tribollet, Eliane ^a   Honer, Michael ^b,c   Prinz, Katja ^b,c   Marguerat, Anouk ^a   Bertrand, Sonia ^a   Bunnelle, William H ^d   Schubiger, P August ^b,c   Meyer, Michael D ^d   Sullivan, James P ^d   Bertrand, Daniel ^a   Westera, Gerrit ^b,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Autoradiography; Brain; Electrophysiology; Imaging; Neuronal nicotinic receptors; Radiolabeling

Indexed keywords

2 CHLORO 3 (4 CHLOROPHENYL) 5 (1 METHYLPYRROLIDIN 2 YLMETHOXY)PYRIDINE; A 183828; A 186253; A 186259; ACETYLCHOLINE; ALPHA BUNGAROTOXIN; CYTISINE; EPIBATIDINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN REGION; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SPECIFICITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SWINE;

ANIMALS; BRAIN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NICOTINIC ANTAGONISTS; PROTEIN BINDING; PYRIDINES; PYRROLIDINES; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SWINE; XENOPUS;

EID: 4544377427     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.05.006     Document Type: Article

References (52)

1. Abraham M.H., Chadha H.S., Mitchell R.C. Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. Journal of Pharmacological Science. 83:1994;1257-1268
2. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Molecular Pharmacology. 45:1994;563-569
3. Bertrand D., Picard F., Le Hellard S., Weiland S., Favre I., Phillips H., Bertrand S., Berkovic S.F., Malafosse A., Mulley J. How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia. 43:2002;112-122
4. Bertrand S., Weiland S., Berkovic S.F., Steinlein O.K., Bertrand D. Properties of neuronal nicotinic acetylcholine receptor mutants from humans suffering from autosomal dominant nocturnal frontal lobe epilepsy. British Journal of Pharmacology. 125:1998;751-760
5. Blower P.J., Clark K., Link E.M. Radioiodinated methylene blue for melanoma targeting: chemical characterisation and tumour selectivity of labelled components. Nuclear Medicine Biology. 24:1997;305-310
6. Brejc K., van Dijk W.J., Klaassen R.V., Schuurmans M., van Der Oost J., Smit A.B., Sixma T.K. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature. 411:2001;269-276
7. Breton J., Pezzi N., Molinari A., Bonomini L., Lansen J., Gonzalez De Buitrago G., Prieto I. Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. European Journal of Biochemistry. 231:1995;563-569
8. Buisson B., Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4(beta)2 nicotinic acetylcholine receptor function. Journal of Neuroscience. 21:2001;1819-1829
9. Burger C., Buck A. Requirements and implementation of a flexible kinetic modeling tool. Journal of Nuclear Medicine. 38:1997;1818-1823
10. Changeux J.P., Edelstein S.J. Allosteric receptors after 30 years. Neuron. 21:1998;959-980
11. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. Journal of Pharmacology and Experimental Therapeutics. 280:1997;346-356
12. Chefer S.I., London E.D., Koren A.O., Pavlova O.A., Kurian V., Kimes A.S., Horti A.G., Mukhin A.G. Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse. 48:2003;25-34
13. Clarke P.B., Schwartz R.D., Paul S.M., Pert C.B., Pert A. Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. Journal of Neuroscience. 5:1985;1307-1315
14. Corringer P.J., Bertrand S., Bohler S., Edelstein S.J., Changeux J.P., Bertrand D. Critical elements determining diversity in agonist binding and desensitization of neuronal nicotinic acetylcholine receptors. Journal of Neuroscience. 18:1998;648-657
15. Corringer P.J., Bertrand S., Galzi J.L., Devillers-Thiery A., Changeux J.P., Bertrand D. Molecular basis of the charge selectivity of nicotinic acetylcholine receptor and related ligand-gated ion channels. Novartis Foundation Symposium. 225:1999;215-224
16. Devillers-Thiery A., Galzi J.L., Eisele J.L., Bertrand S., Bertrand D., Changeux J.P. Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels. Journal of Membrane Biology. 136:1993;97-112
17. Ding Y.S., Molina P.E., Fowler J.S., Logan J., Volkow N.D., Kuhar M.J., Carroll F.I. Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. Nuclear Medicine Biology. 26:1999;139-148
18. Edelstein S.J., Changeux J.P. Allosteric transitions of the acetylcholine receptor. Advance Proteine Chemistry. 51:1998;121-184
19. Fujita M., Tamagnan G., Zoghbi S.S., Al-Tikriti M.S., Baldwin R.M., Seibyl J.P., Innis R.B. Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. Journal of Nuclear Medicine. 41:2000;1552-1560
20. Fujita M., Seibyl J.P., Vaupel D.B., Tamagnan G., Early M., Zoghbi S.S., Baldwin R.M., Horti A.G., Kore N.A., Mukhin A.G., Khan S., Bozkurt A., Kimes A.S., London E.D., Innis R.B. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. European Journal of Nuclear Medicine Molecular Imaging. 29:2002;183-190
21. Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Molecular Pharmacology. 48:1995;774-782
22. Gotti C., Fornasari D., Clementi F. Human neuronal nicotinic receptors. Progress in Neurobiology. 53:1997;199-237
23. Grutter T., Changeux J.P. Nicotinic receptors in wonderland. Trends Biochemistry Science. 26:2001;459-463
24. Itier V., Bertrand D. Mutations of the neuronal nicotinic acetylcholine receptors and their association with ADNFLE. Neurophysiologie Clinique. 32:2002;99-107
25. Jia L., Flotildes K., Li M., Cohen B.N. Nicotine trapping causes the persistant desensitization of alpha 4 beta 2 nicotinic receptors expressed in oocytes. Journal of Neurochemistry. 84:2003;753-766
26. Kassiou M., Scheffel U.A., Ravert H.T., Mathews W.B., Musachio J.L., London E.D., Dannals R.F. Pharmacological evaluation of [11C]A-84543: an enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. Life Science. 63:1998;PL13-18
27. Kassiou M., Bottlaender M., Loc'h C., Dolle F., Musachio J.L., Coulon C., Ottaviani M., Dannals R.F., Maziere B. Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors. Synapse. 45:2002;95-104
28. Langenbuch-Cachat J., Bon C., Mulle C., Goeldner M., Hirth C., Changeux J.P. Photoaffinity labeling of the acetylcholine binding sites on the nicotinic receptor by an aryldiazonium derivative. Biochemistry. 27:1988;2337-2345
29. Le Novere N., Corringer P.J., Changeux J.P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. Journal of Neurobiology. 53:2002;447-456
30. Lentz T.L. Differential binding of nicotine and alpha-bungarotoxin to residues 173-204 of the nicotinic acetylcholine receptor alpha 1 subunit. Biochemistry. 34:1995;1316-1322
31. Lin N.H., Gunn D.E., Li Y., He Y., Bai H., Ryther K.B., Kuntzweiler T., Donnelly-Roberts D.L., Anderson D.J., Campbell J.-E., Sullivan J.P., Arnesic S.P., Holladay M.W. Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy] pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist. Bioorganic & Medicinal Chemistry Letters. 8:1998;249-254
32. Loiacono R., Stephenson J., Stevenson J., Mitchelson F. Multiple binding sites for nicotine receptor antagonists in inhibiting [3H](-)-nicotine binding in rat cortex. Neuropharmacology. 32:1993;847-853
33. Lundqvist H., Langstrom B., Nordberg A. Use of carbon-11 nicotine in PET studies. European Journal of Nuclear Medicine Molecular Imaging. 24:1997;825-826
34. Marks M.J., Smith K.W., Collins A.C. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. Journal of Pharmacology and Experimental Therapeutics. 285:1998;377-386
35. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annual Revue Physiology. 57:1995;521-546
36. Pabreza L.A., Dhawan S., Kellar K.J. [3H]cytisine binding to nicotinic cholinergic receptors in brain. Molecular Pharmacology. 39:1991;9-12
37. Papke R.L., Heinemann S.F. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Molecular Pharmacology. 45:1994;142-149
38. Patt J.T., Spang J.E., Buck A., Cristina H., Arras M., Schubiger P.A., Westera G. Synthesis and in vivo studies of the stereoisomers of N-[11C]methyl-homoepibatidine. Nuclear Medicine Biology. 28:2001;645-655
39. Perry D.C., Kellar K.J. [3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. Journal of Pharmacology and Experimental Therapeutics. 275:1995;1030-1034
40. Perry D.C., Xiao Y., Nguyen H.N., Musachio J.L., Davila-Garcia M.I., Kellar K.J. Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. Journal of Neurochemistry. 82:2002;468-481
41. Qian C., Li T., Shen T.Y., Libertine-Garahan L., Eckman J., Biftu T., Ip S. Epibatidine is a nicotinic analgesic. European Journal of Pharmacology. 250:1993;R13-14
42. Quik M., Choremis J., Komourian J., Lukas R.J., Puchacz E. Similarity between rat brain nicotinic alpha-bungarotoxin receptors and stably expressed alpha-bungarotoxin binding sites. Journal of Neurochemistry. 67:1996;145-154
43. Roger G., Lagnel B., Rouden J., Besret L., Valette H., Demphel S., Gopisetti J., Coulon C., Ottaviani M., Wrenn L.A., Letchworth S.R., Bohme G.A., Benavides J., Lasne M.C., Bottlaender M., Dolle F. Synthesis of a [2-Pyridinyl-18F]-labelled fluoro derivative of (-)-Cytisine as a candidate radioligand for brain nicotinic alpha4beta2 receptor imaging with PET. Bioorganical Medicine Chemistry. 11:2003;5333-5343
44. Saji H., Ogawa M., Ueda M., Iida Y., Magata Y., Tominaga A., Kawashima H., Kitamura Y., Nakagawa M., Kiyono Y., Mukai T. Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Annual Nuclear Medicine. 16:2002;189-200
45. Seiler N., Knodgen B. Identification of amino acids in picomole amounts as their 5-dibutylaminonaphthalene-1-sulphonyl derivatives. Journal of Chromatography. 97:1974;386-388
46. Sihver W., Langstrom B., Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurologica Scandinavica Supplementum. 176:2000;27-33
47. Skok M.V., Voitenko L.P., Voitenko S.V., Lykhmus E.Y., Kalashnik E.N., Litvin T.I., Tzartos S.J., Skok V.I. Alpha subunit composition of nicotinic acetylcholine receptors in the rat autonomic ganglia neurons as determined with subunit-specific anti-alpha(181-192) peptide antibodies. Neuroscience. 93:1999;1427-1436
48. Spang J.E., Patt J.T., Westera G., Schubiger P.A. Comparison of N-[(11)C]methyl-norchloroepibatidine and N-[(11)C]methyl-2-(2-pyridyl)-7- azabicyclo[2.2.1]heptane with N-[(11)C]methyl-epibatidine in small animal PET studies. Nuclear Medicine Biology. 27:2000;239-247
49. Strijckmans V., Coulon C., Kassiou M., Loc'h C., Maziere B. In vitro pharmacological properties of 4-bromodexetimide for muscarinic receptors. Life Science. 58:1996;L337-344
50. Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C.H., Adams P., Piattoni-Kaplan M., Buckley M.J., et al. (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics. 271:1994;624-631
51. Young R.C., Mitchell R.C., Brown T.H., Ganellin C.R., Griffiths R., Jones M., Rana K.K., Saunders D., Smith I.R., Sore N.E., et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. Journal of Medicine Chemistry. 31:1988;656-671
52. Zoli M., Lena C., Picciotto M.R., Changeux J.P. Identification of four classes of brain nicotinic receptors using beta2 mutant mice. Journal of Neuroscience. 18:1998;4461-4472